

**Drug-Overdose Mortality and Previous-Year Illicit-Drug Use among High-School-Aged Adolescents in the United States.**

Panel A shows annualized monthly overdose deaths among adolescents 14 to 18 years of age between January 2018 and December 2022. Data are from the Centers for Disease Control and Prevention WONDER system. Data from 2022 are provisional. Panel B shows the percentage of 12th graders reporting use of illicit substances (besides cannabis) in the previous 12 months, between 2002 and 2022. Adapted from the Monitoring the Future survey (<https://monitoringthefuture.org/data/>). Specific question wording has shifted in minor ways over time.

and December 2021 had a known mental health problem or history of receiving mental health care, whereas only 11% had a history of receiving substance-use treatment.<sup>3</sup>

Since many adolescents may use fentanyl unknowingly, widespread implementation of up-to-

date overdose-prevention education is essential. Most overdose deaths in adolescents (84%) are categorized as unintentional deaths. Pediatricians, other primary care clinicians, and mental health practitioners who see adolescents could routinely ask their patients

whether they or their peers have been approached about purchasing pills, including on social media, or have used pills that weren't prescribed to them. Many pediatricians already universally screen adolescents for substance use, which can serve as an intro-

duction to a conversation about fentanyl. Clinicians can provide adolescents and family members with anticipatory guidance about counterfeit pills, signs of an overdose, and how to intervene in the event of an overdose.

Educators and parents can convey clear messages about the risk associated with fentanyl and counterfeit pills. Alcohol, nicotine, and cannabis remain the substances most commonly used by adolescents — and therefore deserve to be a focus of home- and school-based substance-use prevention programming — but are rarely implicated in drug-poisoning deaths. The focus of programming could be expanded to include education on fentanyl, counterfeit pills, naloxone, and techniques for reducing risk. Such programming should avoid using fear-based tactics and instead promote adolescents' strengths, including their capacity for careful decision making, desire for safety, and resilience.

Clinicians, educators, and parents can draw inspiration from the Safety First curriculum, which presents abstinence from drugs as the safest choice for adolescents but also provides information about risk reduction for those who choose to experiment with drugs. Messaging should include the recommendation to never use drugs alone, so that someone is available to intervene in the event of an overdose; information about where to find and how to use the overdose-reversal agent naloxone, which recently became available over the counter; and guidance to call emergency services in the event of an overdose, including reassurance that doing so won't result in criminal penalties (in states that have Good Samaritan laws providing such protections).

Education would ideally be coupled with the provision of naloxone in schools — an approach recently implemented by numerous districts and recommended broadly by the Biden administration. Schools could also adopt “no questions asked” pill-disposal programs and provide students with anonymous mechanisms — such as messaging services — to ask questions about counterfeit pills and other substance use without risking punishment or shame.

Social media contributes to risk — but also offers opportunities — in this area. Counterfeit pills are commonly marketed to adolescents on social media platforms. These platforms are also sources of health information for adolescents, however, and therefore places where overdose-prevention education can occur. Public health agencies are often unsuccessful at building large followings of adolescents on social media, but they can partner with social media users who already have large followings (many of whom are adolescents) to disseminate accurate information. Social media platforms should strive to verify accounts that provide high-quality educational information and elevate their posts in their algorithms. Many recent overdose-prevention efforts, including efforts to expand access to naloxone in schools, have been spurred by activism among adolescents, often after the deaths of their peers. Adolescents should be recognized and empowered as agents who can drive change.

In addition, any long-term, sustainable strategy for addressing the adolescent overdose crisis will require the widespread availability of high-quality mental health care and addiction treatment. Mental health problems among


adolescents have become considerably more common over the past decade — particularly depressive symptoms and suicidal ideation, according to CDC data, both of which can intensify substance use. Access to mental health care and substance-use treatment is often hampered by long wait times and high costs, and adolescents may be reluctant to seek care because of stigma. Mental health services should be available at minimal cost to families and with little or no wait, including in schools and other places that adolescents frequent.

Similarly, low-barrier and evidence-based addiction treatment should be available to adolescents, and steps should be taken to reduce the stigma associated with seeking treatment. Recent data suggest that only one in four residential addiction-treatment facilities for adolescents offers buprenorphine, the standard-of-care medication for OUD treatment in this age group.<sup>5</sup> The recent elimination of the X-waiver requirement for prescribing buprenorphine creates new treatment opportunities; primary care clinicians can now more easily offer evidence-based buprenorphine treatment to adolescents in general medical settings.

Throughout, interventions will need to address disparities in overdose deaths based on race and ethnicity. Such mortality among non-Hispanic American Indian or Alaska Native adolescents was 1.82 times as high as that among non-Hispanic White adolescents between 2020 and 2022. Investment in Native-led, culturally appropriate substance-use prevention and treatment approaches will therefore be essential.

There are also geographic hotspots of adolescent overdose

deaths, many of which are in the western United States. Arizona, Colorado, and Washington State had mortality nearly twice the national average or higher in 2020–2022. An assessment of hotspot counties — defined as those that had at least 20 overdose deaths and mortality higher than the national average during this period — revealed 19 counties of high concern. Maricopa County, Arizona, and Los Ange-

 **An audio interview with Joseph Friedman is available at NEJM.org** les County, California, had the highest number of fatal overdoses, with 117 and 111 deaths, respectively. School-based interventions could be prioritized in these counties.

The U.S. overdose crisis is af-

fecting Americans at younger ages — even as adolescent substance use is decreasing. In response, parents, physicians, and educators must equip adolescents with the knowledge and tools they need to keep themselves safe, and adolescents must be supported with stronger mental health and addiction services.

Disclosure forms provided by the authors are available at NEJM.org.

From the Center for Social Medicine and Humanities, University of California, Los Angeles, Los Angeles (J.F.); and the Division of Adolescent and Young Adult Medicine, Mass General for Children, and the Department of Pediatrics, Harvard Medical School — both in Boston (S.E.H.).

This article was published on January 6, 2024, at NEJM.org.

1. Goldstick JE, Cunningham RM, Carter PM. Current causes of death in children and adolescents in the United States. *N Engl J Med* 2022;386:1955-6.
2. Friedman J, Godvin M, Shover CL, Gone JP, Hansen H, Schriger DL. Trends in drug overdose deaths among US adolescents, January 2010 to June 2021. *JAMA* 2022;327:1398-400.
3. Tanz LJ, Dinwiddie AT, Mattson CL, O'Donnell J, Davis NL. Drug overdose deaths among persons aged 10–19 Years — United States, July 2019–December 2021. *MMWR Morb Mortal Wkly Rep* 2022;71:1576-82.
4. Palamar JJ, Ciccarone D, Rutherford C, Keyes KM, Carr TH, Cottler LB. Trends in seizures of powders and pills containing illicit fentanyl in the United States, 2018 through 2021. *Drug Alcohol Depend* 2022;234:109398.
5. King C, Beetham T, Smith N, et al. Treatments used among adolescent residential addiction treatment facilities in the US, 2022. *JAMA* 2023;329:1983-5.

DOI: 10.1056/NEJMp2312084

Copyright © 2024 Massachusetts Medical Society.

## Accuracy and Equity in Clinical Risk Prediction

Emma Pierson, Ph.D.

When I was 19 years old, I learned that my mother carried a *BRCA1* mutation, which confers a high risk of breast and ovarian cancer. I've spent much of my life since then thinking about risk. As I waited to find out whether I had inherited the mutation, I tried to come to terms with what it meant to have an exactly 50% risk of having it. "Sometimes I feel that I know I don't have it," I wrote in my diary. But a second later, I dismissed that idea as irrational. When I learned that I carried the mutation, I began, at age 25, the annual MRIs recommended for high-risk women. I began thinking about false-positive and false-negative risks from screening — the imperfections of mammography that necessitate MRIs for young women with my mutation, the unreliable results of ovarian

cancer screening tests that render them mostly useless. Now, as a 32-year-old trying to plan with my girlfriend when we will have children, I wish desperately that doctors could tell me precisely how my risk of ovarian cancer will climb year by year: How long can we safely wait?

Health risk estimates have shaped my most important life decisions. This has convinced me that we have a profound obligation to patients to predict their risks as accurately as possible. As a professor of computer science and population health, I build algorithms that predict health risks, with a particular focus on ensuring that they perform equitably across groups.

Over the past few years, I've seen a welcome and overdue surge of interest in algorithmic equity. But I've also watched, disquieted,

as my field has sometimes — with the laudable intention of ensuring equity — deviated from our basic mandate to predict patients' risk as accurately as possible. Equity and accuracy need not conflict — improving the accuracy of risk prediction can often improve equity as well — but we have made choices that reduce accuracy in the name of equity, ultimately achieving neither.

One key example is the explosion of "debiasing" methods — turnkey technical solutions that can be run on any clinical algorithm, even in settings in which they make little sense, as recent reviews have documented.<sup>1</sup> Frequently, these methods seek to achieve equity by equalizing some measure across two groups. For example, they might try to equalize the fraction of people in each group — men and women, or